Moscow, December, 11 2012 – Pharmstandard OJSC (LSE: PHST IL, MICEX-RTS: PHST RU), Russia’s leading pharmaceutical company, announces the signing of a partnership agreement with AVVA Rus OJSC.
On December 10, 2012 Pharmstandard OJSC and AVVA Rus OJSC signed a partnership agreement for manufacturing, promotion and distribution of the following product brands in Russia: Mikrazim®, Filtrum®, Laktofiltrum® and Ursogliv®.
This partnership agreement will allow to offer the most attractive terms of shipment to distributors and pharmacy chains, as well as to implement a successful marketing strategy.
Pharmstandard OJSC informs that it has no further M&A plans for the rest of 2012. The Company made 2 acquisitions this year – 50.1% in Big Pearl Trading Ltd. and 100% in LEKKO OJSC. Total sum of investments does not exceed $80m.
Contacts:
|
Pharmstandard OJSC |
AVVA Rus OJSC |
|
Pharmstandard OJSC Phone: (495) 970-0030 ext.2824 Fax: (495) 970-0032 |
Alexei Egorov AVVA RUS OJSC |
About Pharmstandard:
Pharmstandard OJSC (www.pharmstd.com/ru) – Russia’s leading pharmaceutical company, that develops and manufactures high-quality modern pharmaceutical products which meet the requirements of the healthcare system and the expectations of patients.
The Company’s production assets consist of 5 pharmaceutical plants located in Kursk, Ufa, Tomsk, Vladimir and in Ukraine’s Kharkov and 1 medical equipment plant in Tyumen.
The most popular Pharmstandard products today are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphoglive®, Amixin®, Afobazol®, Rastan® and Biosulin®. The Company manufactures more than 250 pharmaceutical products; More than 100 Pharmstandard products (taking into account all forms and dosages) are included in the list of Vital and Essential Pharmaceuticals.
Pharmstandard’s shares and GDRs are traded on the RTS-MICEX and LSE, respectively.
About AVVA RUS:
AVVA RUS – a pharmaceutical production company; forms a pharmaceutical Holding company along with AVVA Pharmaceuticals AG (Switzerland). The Holding company was organized on the basis of a partnership agreement between top management of “STI-MED-SORB” plant and AVVA Pharmaceuticals AG (Switzerland).
| Back | Print out |
